ObjectiveTo explore the effect of neoadjuvant combined postoperative therapy on patients with hepatocellular carcinoma after radical operation. Methods41 postoperative cases were divided into 2 groups at random with 20 cases receiving hepatic artery chemotherapy embolization and biotherapy, and 21 cases receiving supporting treatment only.Results The intrahepatic tumor recurrence rate at 1 year and 2 years in treatment group was 10% (2/20) and 30% (6/20), compared with 43% (9/21) and 62% (13/21) in control group (all P

Objective To study the relationship of immunophenotype and prognosis of acute leukemia(AL). Methods 75 patients with AL were analyzed immunophenotype expression by FCM and evaluated the effect of differ-ent immunophenotype to prognosis. Results (1) The incidence of CD13, CD33, CD64, CD117 expression in AML was 82%. The incidence of CD2, CD3, CD7, CD19, CD20 expression in ALL was 88%. The incidence of lymphocytic lineage antigen expression in AML(Ly + AML) was 13% and myeloid lineage antigen expression in ALL(My + ALL) was 11%. (2)According to the antigen expression, AL could be classified into three subgroups:lineage-specific expres-sion;mixture-lineage expression and null type. The lineage-specific expression was the highest in AML and ALL, and had a better clinical prognosis. The null type was the lowest neither in AML nor ALL and had a poorer clinical progno-sis. In mixture-lineage expression the CR rate of AML with CD7+ was the lowest than those with lineage-specific ex-pression and had poorer prognosis. Conclusions AL immtmophenotype might be devided into three subgroups:line-age-specific expression; mixture-lineage expression and null type. In the patients with CD7+ AML and null type ex-pression,lower CR rate and poorer prognosis were seen than those with lineage-specific expression. It needed to ex-plore new treatment methods.

Objective To study the effect of rhein on the process of tubular epithelial-mesenchymat transformation in kidney of diabetic rats. Methods Wistar male rats were randomly assigned to 3 groups: Control group (N group, n=12),diabetic group(D group, n=12), rhein treatment group(R group, n=12).The rats of rhein treatment group were treated with daily intragastric administration of periment. The excretion of urinary protein and serum creatine were measured. Histological changes of renal tissue were observed by HE and MASSON stain. Immunohistochemistry was performed to investigate the expression of E-cadherin, α-SMA,FN and TGF-β1 in kidney. Results Compared with the control group, the tubulointerstitial injury and the accumulation of extraeellular matrix protein in diabetic models were obvious(P＜0.01).Compared with the control group, the expression of E-cadherin was decreased significantly and the expression of α-SMA,FN and TGF-β1 was increased significantly in diabetic group. E-cadherin was negatively correlated with TGF-β1(rs=-0.60,P＜0.05),α-SMA and FN was positively correlated with TGF-β1(rs=0.88,P＜0.05;rs:0.91,P＜0.01).In comparison with diabetic group,rhein could up-regulate the expression of E-cad and down-regulate the expression of α-SMA and FN in renal tubular epithelial cells(P＜0.01).Conclusion Rhein could protect kidney by ameliorating interstitial fibrosis in diabetic rats. The mechanism may be depend on down-regulating the expression of TGF-β1 and suppressing tubular epithelial-mesenchymal transformation.

Human bioequivalence testing is an important part of evaluating the quality of a formulation. Although these drugs have a large amount of safety data and clinical application data, they may still have ethical risks in healthy subjects. The definition of healthy volunteers, the general inclusion and exclusion criteria, auxiliary inclusion and exclusion criteria, and inclusion and exclusion criteria considering drug specificity are summarized. The basis for determining whether abnormal test values are clinically significant when screening healthy subjects and the considerations for improving the screening pass rate are discussed. It is expected to provide useful reference for the smooth implementation of human bioequivalence testing.